Loading clinical trials...

Lipids, Inflammation, and CV Risk in RA | Clinical Trials | Clareo Health

COMPLETED

Lipids, Inflammation, and CV Risk in RA

Lipids, Inflammation, and Cardiovascular Risk in Rheumatoid Arthritis

NCT02714881•Brigham and Women's Hospital

Summary

The objective of this study was to examine the relationship between inflammation, lipids, and cardiovascular risk in rheumatoid arthritis. The central hypothesis is that reducing inflammation will reduce cardiovascular risk as measured by coronary flow reserve. Additionally, we hypothesized that lipid levels may have a weaker correlation with CV risk compared to the general population.

Eligibility

Age

35 - 90 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•RA diagnosed by a rheumatologist
•Fulfills the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Criteria for RA
•Age\>35
•Active RA as defined by treating rheumatologist
•Biologic DMARD naive

Exclusion Criteria

•Patients on statin or PCSK9 inhibitor therapy
•Corticosteroid therapy \>10mg prednisone or its equivalent as a maintenance treatment
•Pregnancy
•Unstable angina (chest pain) or shortness of breath
•Severe valvular heart disease
•Myocarditis
•Pericarditis
•Asthma with active wheezing
•History of lymphoproliferative disease or melanoma (stage two or higher), active malignancy, or cancer treatment in the last 5 years
•Active infectious disease (HIV, Tuberculosis, or Hepatitis B/C)

Locations (1)

Brigham and Women's Hospital

Boston, Massachusetts, United States

Key Dates

Start Date

October 17, 2016

Primary Completion Date

December 14, 2020

Completion Date

December 21, 2022

Last Updated

January 21, 2026

Enrollment

ACTUAL participants

Conditions

Rheumatoid ArthritisCardiovascular Disease

Interventions

Certolizumab

DRUG

Clinical Cohort Construction and Therapeutic Effect Evaluation of Integrated Traditional Chinese and Western Medicine in the Treatment of Rheumatoid Arthritis

NCT07484243

Rheumatoid Arthritis (RA)Rheumatoid Arthritis-Associated Interstitial Lung Disease+1 more

View study

RECRUITINGPHASE2

Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults

NCT03372733

Cardiovascular Disease

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 21, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Lipids, Inflammation, and CV Risk in RA

Inclusion Criteria

Exclusion Criteria

Clinical Cohort Construction and Therapeutic Effect Evaluation of Integrated Traditional Chinese and Western Medicine in the Treatment of Rheumatoid Arthritis

Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

Targeted Remotely-delivered Anti-inflammatory Interventions With Exercise for Rheumatoid Arthritis

Plant-Based Diet for Patients With Rheumatoid Arthritis